ArticleJACC. Basic to translational science2022

A Phase 1 Dose-Escalation Study of the Cardiac Myosin Inhibitor Aficamten in Healthy Participants.

Fady I Malik et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.